Korea‑China biotech comparison shows upfront payments only a third of China's despite similar tech

An analysis compares biotech investment climates in Korea and China. Both countries host promising technologies in the sector. The study finds Korean firms pay significantly lower upfront fees. Upfront payments in Korea are about one‑third of Chinese levels. The cost difference reflects divergent financing practices. Lower fees may affect deal structures and risk allocation. The report suggests investors weigh cost against technology potential. Ongoing monitoring will reveal if the payment gap narrows.